Overweight Clinical Trial
Official title:
Time to Eat Study - Pilot
| Verified date | May 2019 |
| Source | University of Florida |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The goals of this pilot study is to evaluate the safety and feasibility of time restricted feeding in an older adult population.
| Status | Completed |
| Enrollment | 10 |
| Est. completion date | September 5, 2018 |
| Est. primary completion date | September 5, 2018 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 65 Years and older |
| Eligibility |
Inclusion Criteria: - Consent to participate in the study - Men and women = 65 years old - Self-reported difficulty walking ΒΌ mile or climbing a flight of stairs - Self-reported sedentariness (<30 minutes structured exercise per week) - Walking speed <1 m/sec on the 4 m walk test - Able to walk unassisted (cane allowed) - Have a body mass index between 25 - 40 kg/m2 (inclusive) Exclusion Criteria: - Current dietary habits - Fasting >12 hours per day - Actively trying to lose weight by participating in formal weight loss program or significantly restricting calorie intake - Weight loss > 5 lbs in the past month - Medical history or conditions - Resting heart rate of >120 beats per minute, systolic blood pressure > 180 mmHg or diastolic blood pressure of > 100 mmHg - Unstable angina, heart attack or stroke in the past 3 months - Continuous use of supplemental oxygen to manage a chronic pulmonary condition or heart failure - Rheumatoid arthritis, Parkinson's disease or currently on dialysis - Active treatment for cancer in the past year - Insulin dependent diabetes mellitus - Taking medications that preclude fasting for 16 hours (e.g. must be taken with food at least 12 hours apart) - Any condition that in the opinion of the investigator would impair ability to participate in the trial |
| Country | Name | City | State |
|---|---|---|---|
| United States | University of Florida Institute on Aging | Gainesville | Florida |
| Lead Sponsor | Collaborator |
|---|---|
| University of Florida |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | At each follow-up contact (either by phone or in person), participants are asked about any changes to their health or physical function since the previous contact. The changes are documented on the adverse event log. | Week 4 | |
| Primary | Adherence | Adherence to the study intervention is measured using food intake time diary. Participants are considered compliant to the study intervention if he/she fasts between 14 - 18 hours per day for the duration of the 4 week study. | Week 4 | |
| Primary | Retention | Retention is measured by drop-out rate. Participants are considered "completed" if the Week 4 clinic visit is completed. | Week 4 | |
| Primary | Recruitment yields | Recruitment yields is measured by the number of individuals who do not meet the eligibility criteria at the phone interview and/or in-person visit. | Baseline | |
| Secondary | 6 Minute Walk Test | The 6 Minute Walk test measures the amount of distance the participant can complete on a standard walking course in six minutes without running or overexerting themselves. Contraindications for test administration and stopping rules based on American Thoracic Society will be followed. | Baseline and Week 4 | |
| Secondary | Grip Strength | Isometric hand grip strength is a commonly used measure of upper body skeletal muscle function and has been widely used as a general indicator of functional status. | Baseline and Week 4 | |
| Secondary | Montreal Cognitive Assessment | The Montreal Cognitive Assessment is a 30-point assessment of mild cognitive impairment, which assesses the domains of attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Different versions of the test are given at the two time points to avoid learning effects between repeated administrations of the test. | Baseline and Week 4 | |
| Secondary | Fatigability Questionnaire | A self-administered, 26-item questionnaire to measure perceived mental and physical fatigability. | Baseline and Week 4 | |
| Secondary | Body Weight | Body weight will be measured following the removal of excess clothing and shoes with calibrated scales. | Baseline and Week 4 | |
| Secondary | Waist Circumference | Waist circumference is taken at the mid-point between the participant's lowest rib and the top of his/her hip bone. | Baseline and Week 4 | |
| Secondary | Activity Monitor | A wrist activity monitor accelerometer to measure daily activity level is worn for the duration of the 4-week study intervention. | Baseline and Week 4 | |
| Secondary | Systemic Inflammatory biomarkers | Inflammatory biomarkers (CRP and Interleukin-6) are measured by ELISA (enzyme-linked immunosorbent assay). | Baseline and Week 4 | |
| Secondary | Health-related quality of life | Self-administered, 12-item questionnaire to measure health-related quality of life | Baseline and Week 4 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Terminated |
NCT03299881 -
Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss
|
N/A | |
| Completed |
NCT02805478 -
Fat-Associated Cardiovascular Organ Dysfunction
|
||
| Active, not recruiting |
NCT02558920 -
Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
|
||
| Completed |
NCT03759743 -
Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject
|
N/A | |
| Completed |
NCT03610958 -
Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss.
|
N/A | |
| Completed |
NCT03678766 -
CHARGE: Controlling Hunger and ReGulating Eating
|
N/A | |
| Completed |
NCT04430465 -
Effects of Wholegrains on Children's Health (KORN)
|
N/A | |
| Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
| Completed |
NCT05376865 -
Effects of Vitamin D Supplementation on Obesity, Inflammatory and Metabolic Markers
|
N/A | |
| Completed |
NCT03625427 -
Effect of Palmitoleic Acid on C-reactive Protein
|
N/A | |
| Active, not recruiting |
NCT03435445 -
Online Platform for Healthy Weight Loss (POEmaS)
|
N/A | |
| Enrolling by invitation |
NCT05576116 -
Combined Bariatric Surgery and Pancreas After Kidney Transplantation for Type II Diabetics
|
N/A | |
| Recruiting |
NCT05249465 -
Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention
|
N/A | |
| Active, not recruiting |
NCT06023095 -
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
|
Phase 1 | |
| Completed |
NCT03648892 -
Brain Dopamine Function in Human Obesity
|
Early Phase 1 | |
| Not yet recruiting |
NCT05751993 -
Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions
|
N/A | |
| Recruiting |
NCT02887950 -
Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Menopause
|
N/A | |
| Completed |
NCT03097237 -
High Fiber Rye Foods for Weight and Body Fat Reduction
|
N/A | |
| Terminated |
NCT02796144 -
MEtformin and Lorcaserin for WeighT Loss in Schizophrenia
|
Phase 4 |